Abstract
Vedolizumab, a monoclonal antibody targeting α4β7 leukocyte integrins, has demonstrated efficacy for induction and maintenance of remission in ulcerative colitis (UC).1 However, it remains unclear whether oral aminosalicylates should be continued or stopped after treatment escalation to vedolizumab. Singh etal2 have demonstrated no significant difference in clinical remission, clinical response, or mucosal healing rates between patients treated with or without concomitant aminosalicylates at entry in clinical trials of infliximab or golimumab. We evaluate the impact of concomitant oral aminosalicylates on clinical outcomes for vedolizumab-treated UC patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
